Cerevel Therapeutics Holdings Inc
NASDAQ:CERE
Cerevel Therapeutics Holdings Inc
Free Cash Flow
Cerevel Therapeutics Holdings Inc
Free Cash Flow Peer Comparison
Competitive Free Cash Flow Analysis
Latest Figures & CAGR of Competitors
Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Cerevel Therapeutics Holdings Inc
NASDAQ:CERE
|
Free Cash Flow
-$346.1m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$21.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$7.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$7.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
$3.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.9B
|
CAGR 3-Years
25%
|
CAGR 5-Years
13%
|
CAGR 10-Years
27%
|
See Also
What is Cerevel Therapeutics Holdings Inc's Free Cash Flow?
Free Cash Flow
-346.1m
USD
Based on the financial report for Dec 31, 2023, Cerevel Therapeutics Holdings Inc's Free Cash Flow amounts to -346.1m USD.
What is Cerevel Therapeutics Holdings Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-36%
Over the last year, the Free Cash Flow growth was -16%. The average annual Free Cash Flow growth rates for Cerevel Therapeutics Holdings Inc have been -36% over the past three years .